Abstract
Objective: To determine the frequency of H1047R mutation on exon 20 PIK3CA gene in the plasma of hormone recepter positive (HR+) breast cancer (BC) women and its relationship with clinical characteristics of these patients. Subjects: Plasma was separated from venous blood of 141 female HR+ BC patients, have been treating at 108 Military Central Hospital from June 2021 to June 2023. Method: Circulating free DNA (cfDNA) was isolated from plasma by magnetic beads (Thermo Fisher Scientific). The H1047R hotspot mutation on exon 20 PIK3CA gene was detected in 141 plasma samples by an in-house Realtime PCR assay using a wild-type allele-specific blocker. Results: 47/141 samples (33,3 %) had the H1047R mutation. The H1047R mutation was present in all disease stages, both in metastatic and non-metastatic cases. Although, the rates of gene mutation in late-stage, metastatic cancer patients were higher than those in the early-stage, non-metastatic cancer group, there was no statistically significant difference between the two groups (p > 0.05). Whereas it was not linked to other clinical traits of patients with HR+BC, the H1047R mutation was more common in those with liver metastases and in those received Fulvestrant (p < 0.05). Conclusion: Peripheral blood from patients with HR+BC in all stages contained the H1047R mutation on exon 20 of the PIK3CA gene. This mutation frequently developed in patients received Fulvestrant treatment and has been related to liver metastases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.